Akums Drugs & Pharmaceuticals Ltd

NSE: AKUMS BSE: 544222Pharma

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]

₹518

52W: ₹409 — ₹623

PE 70 · Book ₹154 · +236% vs book

Market Cap₹8,152 Cr

Stock P/E70Price to Earnings

ROCE6.82%Return on Capital

ROE4.93%Return on Equity

Div. Yield0%Face Value ₹2

Strengths

+Company is almost debt free.

Weaknesses

−Stock is trading at 3.38 times its book value
−The company has delivered a poor sales growth of 10.0% over past five years.
−Company has a low return on equity of 3.15% over last 3 years.
−Earnings include an other income of Rs.106 Cr.
−Working capital days have increased from 34.5 days to 67.3 days

Shareholding Pattern

Promoters75.26%

FIIs1.38%

DIIs14.36%

Public6.29%

Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	75.26%	75.26%	75.26%	75.26%	75.26%	75.26%	75.26%
FIIs	7.34%	6.36%▼1.0	5.77%▼0.6	4.24%▼1.5	2.27%▼2.0	1.14%▼1.1	1.38%▲0.2
DIIs	7.53%	6.99%▼0.5	7.39%▲0.4	8.85%▲1.5	9.28%▲0.4	14.41%▲5.1	14.36%▼0.1
Public	7.14%	8.64%▲1.5	8.84%▲0.2	8.92%▲0.1	10.46%▲1.5	6.45%▼4.0	6.29%▼0.2

Financial Statements

Metric	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	383	298	317	328	337	329	332	309	369	338
Expenses	351	359	274	285	303	311	288	292	344	327
Operating Profit	32	-61	44	43	34	18	44	17	25	12
OPM %	8%	-20%	14%	13%	10%	5%	13%	5%	7%	3%
Net Profit	29	-58	42	50	41	28	45	23	28	15
EPS ₹	2.05	-4.05	2.84	3.2	2.62	1.75	2.85	1.49	1.79	0.97

AI Insights

Revenue Trend

Mar 2026 revenue at ₹1,349Cr, up 2.8% YoY. OPM at 7%.

Debt Position

Borrowings at ₹59Cr. Debt-to-equity ratio: 0.02x. Healthy balance sheet.

Capex Cycle

CWIP at ₹52Cr (12% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 14.36% (+6.83pp change). FIIs: 1.38% (-5.96pp change). Promoters hold 75.26%.

Margin & Efficiency

ROCE improving from 0% (Mar 2018) to 7% (Mar 2026). Working capital days: 67.

Valuation

PE 70x with 6.82% ROCE. Price is 236% above book value of ₹154. Dividend yield: 0%.